Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Net Cash Flow (2016 - 2026)

Gyre Therapeutics has reported Net Cash Flow over the past 16 years, most recently at -$3.5 million for Q4 2025.

  • Quarterly Net Cash Flow rose 8.93% to -$3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.9 million through Dec 2025, up 216.3% year-over-year, with the annual reading at $24.9 million for FY2025, 216.3% up from the prior year.
  • Net Cash Flow was -$3.5 million for Q4 2025 at Gyre Therapeutics, down from $3.8 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $52.7 million in Q1 2021 and troughed at -$52.3 million in Q3 2022.
  • The 5-year median for Net Cash Flow is -$3.7 million (2024), against an average of -$1.1 million.
  • Year-over-year, Net Cash Flow crashed 372.39% in 2021 and then skyrocketed 1225.82% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$14.8 million in 2021, then crashed by 81.57% to -$26.9 million in 2022, then soared by 174.15% to $19.9 million in 2023, then plummeted by 119.05% to -$3.8 million in 2024, then increased by 8.93% to -$3.5 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Net Cash Flow are -$3.5 million (Q4 2025), $3.8 million (Q3 2025), and $21.4 million (Q2 2025).